- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
Patent holdings for IPC class C07D 213/42
Total number of patents in this class: 148
10-year publication summary
|
9
|
12
|
7
|
13
|
12
|
12
|
4
|
8
|
5
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
8 |
| F. Hoffmann-La Roche AG | 7958 |
5 |
| Gliapharm SA | 21 |
5 |
| Takeda Pharmaceutical Company Limited | 2961 |
4 |
| The University of Melbourne | 499 |
4 |
| Ranbaxy Laboratories Limited | 453 |
3 |
| Grey Wolf Therapeutics Limited | 13 |
3 |
| Mitsui Chemicals Crop & Life Solutions,Inc. | 142 |
3 |
| Glaxo Group Limited | 4496 |
2 |
| BASF SE | 19740 |
2 |
| AstraZeneca AB | 3042 |
2 |
| Janssen Pharmaceutica N.V. | 3839 |
2 |
| Massachusetts Institute of Technology | 9795 |
2 |
| The Johns Hopkins University | 5377 |
2 |
| Concert Pharmaceuticals, Inc. | 254 |
2 |
| Janssen Sciences Ireland UC | 256 |
2 |
| Jazz Pharmaceuticals Ireland Limited | 121 |
2 |
| Kanto Kagaku Kabushiki Kaisha | 88 |
2 |
| Medivir AB | 142 |
2 |
| Nissan Chemical Industries, Ltd. | 1822 |
2 |
| Other owners | 89 |